In this Trending News US episode, Jen, Mindy, and Ryan discuss recent newsworthy items, including the introduction of rebate credits by CVS to account for more biosimilars entering the market, as well as a recent ruling by a federal appeals court that drugmakers cannot restrict 340B program offerings from community and specialty pharmacies. Finally, we discuss a groundbreaking procedure in which a kidney from a CRISPR gene edited pig was transplanted into a human
Podcast Tags: healthcare, healthcare news, CVS health, PBMs, biosimilars, 340B, pharmacies, hospitals, providers, xenotransplantation, CRISPR, gene editing
Source Links:
- As Humira biosimilars take over the market, CVS has created a new ploy; the drug “rebate credit”
- Federal appeals court sides with 340B contract pharmacies
- American Hospital Association 340B Factsheet
- Gene edited pig kidney transplanted into a living patient for the first time
- Kidney Disease Statistics for the United States
Panel – Jen Burke, Mindy McGrath, Ryan Hummel
Research & Production – Anna Briccetti, Jen Burke
Recording & Editing – Mike Liberto, Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
Listen now
Naseem Ahmed appointed judge for the BPLS Inspire Awards
Inizio’s Global Director of Inclusion and Impact, Naseem Ahmed, has been appointed as a judge for the BPLS Inspire Awards.
Read moreSpeed to publication with GenAI: Done the right way
In the last three years, Generative AI (GenAI) has moved from novelty to expectation. Across industries, teams are being asked, whether explicitly or
Read moreInizio Ignite Sparks a New Era of Connected Advisory Solutions
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM.
Read more